Loading clinical trials...
Loading clinical trials...
A Phase 1b/2 Trial to Evaluate the Safety and Efficacy of Radium-223 Dichloride (BAY88-8223) in Combination With Bortezomib and Dexamethasone in Early Relapsed Multiple Myeloma
Conditions
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223)
Placebo
+2 more
Locations
7
United States
Pacific Oncology/Hematology Associates
Encinitas, California, United States
Wake Forest Baptist Health
Winston-Salem, North Carolina, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
National Cancer Center
Goyang-si, Gyeonggido, South Korea
Seoul National University Hospital
Seoul, South Korea
Hospital Universitari Son Espases
Palma de Mallorca, Illes Baleares, Spain
Start Date
February 10, 2017
Primary Completion Date
March 20, 2019
Completion Date
March 20, 2019
Last Updated
February 26, 2020
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions